The probe is directed at all CAR-Ts currently ... positive lymphoma – in patients who had received both types of CAR-T therapy. The regulator highlighted the products by name, including Bristol- ...

CAR-T cell therapy has revolutionized the treatment of relapsed and refractory B-acute lymphoblastic leukemia (B-ALL), with ...

The European Commission (EC) has granted expanded approval to Bristol Myers Squibb’s (BMS) cluster of differentiation 19 ...

Researchers at the University of Colorado Anschutz Medical Campus have successfully developed a supercharged iteration of CAR ...

Despite its promise, autologous chimeric antigen receptor T-cell (CAR T-cell) therapy faces several challenges, including limited accessibility, high costs and manufacturing bottlenecks. Allogeneic ...

CAR T-cell therapy, as defined by the National Cancer Institute, utilizes a patient’s T cells, part of the immune system, which are extracted, changed in a laboratory to attack cancer cells, grown in ...

New research shows that GD2 CAR-T cell therapy offers a potential cure for neuroblastoma, with some patients achieving long-term remission for over a decade—marking a major milestone in solid ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Researchers have successfully developed a supercharged iteration of CAR-T cell therapy that can enhance the effectiveness and longevity of the cells, particularly against cancer cells that are harder ...

CAR-T cell therapy involves extracting a patient’s T-cells, modifying them to recognize cancer cells, and then reinfusing them into the patient where they target cancer cells throughout the body.